Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women

NCT02463032 is registered in ClinicalTrials.gov with GTx as lead sponsor.

NCT NCT02463032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02463032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Lead sponsor
GTx
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2015
Completion date
March 31, 2019
Enrollment
136 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

er+ and ar+ breast cancer